Institution:


Epigenètica del Càncer
Manel Esteller Badosa
Carlos García Prieto
Experimental design developed to detect DNA methylation changes in patient T cells upon CAR transduction
Urgent need to predict the intensity and duration of the CAR T-cell therapy response, and the risk to develop severe adverse effects
Personalized medicine, a diagnostic kit that predicts response and toxicity of CAR T-cell therapy with >80% accuracy
Cancer therapy
DNA methylation can predict clinical outcome and survival to CAR T-cell therapy
Patented (EP21382168.9; EP21382815.5; PCT/EP2022/054803)
Pharmaceutical companies
TRL: 4
CRL: N/A
BRL: N/A
IPRL: N/A
TmRL: N/A
FRL: N/A
Impacted SDGs:
N/A
if you want to know more about this project do not hesitate to contact us